Close
Oncology
In 2008 there were 12 million new cancer cases and seven million cancer deaths worldwide; this number is projected to double by 2030.1 Siemens Healthcare Diagnostics offers a wide range of oncology and associated immunoassays to assist in the early detection, treatment and monitoring of cancer. Our oncology menu includes pioneering, proprietary assays for common cancers that expand the breadth of service your laboratory can deliver, such as Serum HER-2/neu and Complexed PSA. Cutting-edge tumor markers from Siemens provide physicians with more choice and information for improved clinical decision-making.
Siemens Tumor Markers include:
- AFP
- BR 27.29
- CA 125 II (OM-MA)
- CA 15-3 (BR-MA)
- CA 19-9 (GI-MA)
- CEA
- cPSA
- fPSA
- PSA
- Serum HER-2/neu
- Third Generation PSA
- TPS†
Leading the Way Toward Oncology Solutions
Siemens is committed to transforming cancer care by bringing together in vivo imaging technologies with in vitro diagnostics (IVD) through innovative information technology. Our goal is to provide integrated, performance-driven oncology solutions that improve patient outcomes, optimize clinical workflow, and bring personalized medicine to patients around the world.
†Not all assays are available in all markets.
1: http://www.cancer.org/docroot/NWS/content/NWS_1_1x_Leading_Cancer_Organizations_Team_Up_For_Global_Cancer_Fight.asp
